Clinical Trial Update: Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE) [Phase 3]

View source ↗

Summary

A Phase 3 trial (CHOICE) assessed adalimumab in moderate-to-severe Crohn's disease patients with prior infliximab exposure; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED